Summary
This 8-K filing from Schering-Plough Corporation (note: the provided text states Schering-Plough, not Merck & Co., Inc.) on April 21, 2005, primarily serves to report the company's financial results for the first quarter of 2005. The report includes a press release detailing these results and supplemental financial data. Investors should pay close attention to the forward-looking statements section, which outlines numerous risks and uncertainties that could impact future performance.
Key Highlights
- 1Schering-Plough Corporation reported its financial results for the first quarter of 2005.
- 2The filing includes a press release (Exhibit 99.1) and supplemental financial data (Exhibit 99.2) related to the Q1 2005 results.
- 3A significant portion of the report is dedicated to disclosing forward-looking statements and associated risks.
- 4Key risk factors mentioned include fluctuations in distributor buying patterns, competitive pressures (including from generic and OTC products), pricing pressures from healthcare organizations, potential impacts of healthcare legislation (like the Medicare Prescription Drug Act), patent uncertainties, regulatory approval processes, manufacturing issues, product development challenges, post-marketing concerns, and the impact of major product performance.
- 5The company lists several major products that accounted for a material portion of 2004 revenues, including CLARITIN, CLARINEX, INTRON A, PEG-INTRON, REBETOL Capsules, REMICADE, TEMODAR, and NASONEX.
- 6The company also highlights potential impacts on sales of ZETIA and VYTORIN.
- 7Schering-Plough explicitly states it does not assume the obligation to update any forward-looking statements.